CAL
ACRV icon

Capital Advisors Ltd’s Acrivon Therapeutics ACRV Stock Holding History

Capital Advisors Ltd’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-48
Closed – – 1310
2024
Q4 		$0 Hold
48
– – ﹤0.01% 1341
2024
Q3 		$0 Hold
48
– – ﹤0.01% 1340
2024
Q2 		$0 Hold
48
– – ﹤0.01% 1345
2024
Q1 		$0 Buy
+48
New +$223 ﹤0.01% 1323

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Advisors Ltd's ACRV Position: Q1 2025 in Review

Capital Advisors Ltd sold out of Acrivon Therapeutics (ACRV) in Q1 2025, closing a stake of 48 shares.

Capital Advisors Ltd first reported a position in ACRV in Q1 2024 and held it in 4 quarters. The position peaked at $0 in Q4 2024. 63 funds tracked by Wall St. Rank hold ACRV as of Q1 2025.

  • Capital Advisors Ltd reported no remaining Acrivon Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Capital Advisors Ltd sold 48 Acrivon Therapeutics shares in Q1 2025.
  • Capital Advisors Ltd first reported a position in Acrivon Therapeutics in Q1 2024 and held it in 4 quarters.
  • Capital Advisors Ltd's Acrivon Therapeutics position peaked at $0 in Q4 2024.
  • 63 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2025.

Based on Capital Advisors Ltd's 13F filing for Q1 2025, filed 15 Apr 2025.